229 related articles for article (PubMed ID: 22962326)
1. Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer.
Morad SA; Levin JC; Shanmugavelandy SS; Kester M; Fabrias G; Bedia C; Cabot MC
Mol Cancer Ther; 2012 Nov; 11(11):2352-61. PubMed ID: 22962326
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53.
Morad SA; Madigan JP; Levin JC; Abdelmageed N; Karimi R; Rosenberg DW; Kester M; Shanmugavelandy SS; Cabot MC
Biochem Pharmacol; 2013 Apr; 85(8):1057-65. PubMed ID: 23353700
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.
Morad SA; Cabot MC
Biochim Biophys Acta; 2015 Sep; 1851(9):1134-45. PubMed ID: 25964209
[TBL] [Abstract][Full Text] [Related]
4. Novel off-target effect of tamoxifen--inhibition of acid ceramidase activity in cancer cells.
Morad SA; Levin JC; Tan SF; Fox TE; Feith DJ; Cabot MC
Biochim Biophys Acta; 2013 Dec; 1831(12):1657-64. PubMed ID: 23939396
[TBL] [Abstract][Full Text] [Related]
5. Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen.
Furlong SJ; Mader JS; Hoskin DW
Oncol Rep; 2006 May; 15(5):1385-90. PubMed ID: 16596215
[TBL] [Abstract][Full Text] [Related]
6. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
7. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism.
Maurer BJ; Melton L; Billups C; Cabot MC; Reynolds CP
J Natl Cancer Inst; 2000 Dec; 92(23):1897-909. PubMed ID: 11106681
[TBL] [Abstract][Full Text] [Related]
8. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells.
Lucci A; Han TY; Liu YY; Giuliano AE; Cabot MC
Cancer; 1999 Jul; 86(2):300-11. PubMed ID: 10421266
[TBL] [Abstract][Full Text] [Related]
10. Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.
Morad SAF; Davis TS; MacDougall MR; Tan SF; Feith DJ; Desai DH; Amin SG; Kester M; Loughran TP; Cabot MC
Biochem Pharmacol; 2017 Apr; 130():21-33. PubMed ID: 28189725
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approaches.
Chapman JV; Gouazé-Andersson V; Messner MC; Flowers M; Karimi R; Kester M; Barth BM; Liu X; Liu YY; Giuliano AE; Cabot MC
Biochem Pharmacol; 2010 Aug; 80(3):308-15. PubMed ID: 20385104
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
13. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
Tran MA; Smith CD; Kester M; Robertson GP
Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer.
Jiang Y; DiVittore NA; Kaiser JM; Shanmugavelandy SS; Fritz JL; Heakal Y; Tagaram HR; Cheng H; Cabot MC; Staveley-O'Carroll KF; Tran MA; Fox TE; Barth BM; Kester M
Cancer Biol Ther; 2011 Oct; 12(7):574-85. PubMed ID: 21795855
[TBL] [Abstract][Full Text] [Related]
15. C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth.
Flowers M; Fabriás G; Delgado A; Casas J; Abad JL; Cabot MC
Breast Cancer Res Treat; 2012 Jun; 133(2):447-58. PubMed ID: 21935601
[TBL] [Abstract][Full Text] [Related]
16. Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia.
Morad SA; Ryan TE; Neufer PD; Zeczycki TN; Davis TS; MacDougall MR; Fox TE; Tan SF; Feith DJ; Loughran TP; Kester M; Claxton DF; Barth BM; Deering TG; Cabot MC
J Lipid Res; 2016 Jul; 57(7):1231-42. PubMed ID: 27140664
[TBL] [Abstract][Full Text] [Related]
17. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
18. Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells.
Kallio A; Zheng A; Dahllund J; Heiskanen KM; Härkönen P
Apoptosis; 2005 Dec; 10(6):1395-410. PubMed ID: 16215679
[TBL] [Abstract][Full Text] [Related]
19. Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen.
Morad SAF; MacDougall MR; Abdelmageed N; Kao LP; Feith DJ; Tan SF; Kester M; Loughran TP; Wang HG; Cabot MC
Exp Cell Res; 2019 Aug; 381(2):256-264. PubMed ID: 31112736
[TBL] [Abstract][Full Text] [Related]
20. Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma.
Tagaram HR; Divittore NA; Barth BM; Kaiser JM; Avella D; Kimchi ET; Jiang Y; Isom HC; Kester M; Staveley-O'Carroll KF
Gut; 2011 May; 60(5):695-701. PubMed ID: 21193455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
